2:09 PM
 | 
Dec 01, 2017
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Mavupharma raises 20M in series A round for STING modulators

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated.

Mavupharma is developing orally bioavailable, non-nucleotide agonists of the transmembrane protein 173 (STING; TMEM173) pathway to treat cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma is using non-nucleotide small molecules to...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >